Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/48718
Title: Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer
Authors: Valerón, Pilar F. 
Chirino, Ricardo 
Fernandez, Leandro 
Torres, Santiago
Navarro Bosch, Domingo 
Aguiar Bautista, José Alberto 
Cabrera, Juan J. 
Diaz-Chico, Bonifacio N. 
DiazChico, JC 
UNESCO Clasification: 32 Ciencias médicas
320101 Oncología
Keywords: Polymerase Chain-Reaction
Growth-Factor-Receptor
Neu Oncogene
Protein Overexpression
Amplification, et al
Issue Date: 1996
Journal: International Journal of Cancer 
Abstract: HER-2/neu oncogene status and total cellular p185(HER-2) content were simultaneously analyzed in 415 invasive breast-cancer specimens by differential PCR and ELISA respectively. Mathematical analysis of the data led us to establish a cut-off value of 1.7 for the ratio between the intensity of the HER-2/neu gene band and the reference gene band, to consider the HER-2/neu gene amplified, and of 260 fmol/mg protein, to consider p 185(HER-2) over-expressed. Of the 415 tumors studied, 15% showed a diverse degree of HER-2/neu gene amplification. Of these tumors, 87% showed over-expression of the p185(HER-2). Of the remaining 352 specimens that did not display HER-2/neu gene amplification, 97% showed no p185(HER-2) over-expression (P < 0.0001). In 40 selected samples with a p185(HER-2) level lower than 260 fmol/mg protein, the degree of p185(HER-2) phosphorylation was very low or undetectable. Conversely, 38 of 46 selected tumors with a p185(HER-2) level higher than 260 fmol/mg protein exhibited a considerable degree of p185(HER-2) phosphorylation (P < 0.0001). Our data suggest that: (i) differential PCR and ELISA, which are relatively simple procedures, give similar information on HER-2/neu status in breast cancer; and (ii) given the large series analyzed, the cutoff values established can be considered as safe values for determining whether, in a given tumor, the HER-2/neu oncogene is amplified or p185(HER-2) is over-expressed.
URI: http://hdl.handle.net/10553/48718
ISSN: 0020-7136
DOI: 10.1002/(SICI)1097-0215(19960117)65:2<129::AID-IJC1>3.0.CO;2-0
Source: International Journal Of Cancer[ISSN 0020-7136],v. 65 (2), p. 129-133 (Enero 1996)
Appears in Collections:Artículos
Show full item record

SCOPUSTM   
Citations

22
checked on Jun 26, 2022

WEB OF SCIENCETM
Citations

21
checked on Jun 26, 2022

Page view(s)

28
checked on May 28, 2022

Google ScholarTM

Check

Altmetric


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.